Platino-resistance in Ovarian Cancer
This study aims to understand why some ovarian cancers become resistant to platinum-based chemotherapy, a common treatment. Researchers will follow women with epithelial ovarian cancer, collecting their health information and biological samples (like blood and tumour tissue) over five years. These samples and details will be gathered during their usual hospital visits, so no extra procedures are needed just for the study. The goal is to identify factors that make treatment less effective, which could lead to better treatments in the future. By studying how the cancer responds to standard treatments, scientists hope to find new ways to help patients whose cancer is harder to treat.
Em resumo
Sobre o que é este estudo?
Imagine you have ovarian cancer, and your doctors recommend a standard type of chemotherapy. For many people, this treatment works well to shrink the cancer. But for some, the cancer becomes 'resistant' to the chemotherapy, meaning the drugs stop working as effectively.
This study is trying to understand why this happens. It's called "Platino-resistance in Ovarian Cancer" because 'platino' refers to the platinum-based chemotherapy drugs. Researchers want to find out what makes these powerful drugs less effective in certain ovarian cancers. They'll do this by carefully collecting information and samples from women who are already undergoing these treatments.
Over five years, doctors will gather details about each patient's health, their illness, and how they respond to treatment. They'll also collect biological samples, like blood, tumour tissue, and fluid that can sometimes build up in the tummy (called ascites). Importantly, these samples will be taken at the same time as routine tests you'd have anyway, so you won't need any extra needles or biopsies just for the study. By looking closely at all this information, scientists hope to discover patterns and factors that lead to chemotherapy resistance, ultimately aiming to develop more effective treatments for future patients.
Pontos principais
- Study aims to understand chemotherapy resistance in ovarian cancer.
- No new treatments, you receive standard care.
- No extra tests or biopsies for the study.
- Your health information and samples will be collected over five years.
- Participation helps future patients, no direct personal medical benefit.
- Você pode parar de participar a qualquer momento.
Quem pode ser elegível?
To be part of this study, you would need to be at least 18 years old and have a specific type of ovarian cancer called 'epithelial ovarian cancer' that has been newly diagnosed. You should also be about to start treatment with platinum-based chemotherapy, or have already started initial treatment for it.
There are also some conditions that would mean you couldn't join. For example, if your ovarian tumour is not the 'epithelial' type or is just 'borderline', or if your cancer has come back after previous treatment, you wouldn't be eligible. Also, if you are pregnant or breastfeeding, or if there are other personal situations that might make it hard for you to attend follow-up appointments, you wouldn't be able to take part.
Finally, to join the study, you would need to understand what's involved and sign a consent form, agreeing to participate. You also need to be covered by the French social security system, as the study is taking place in France.
Este estudo pode ser adequado para você?
Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.
- Você tem pelo menos 18 anos?
- Do you have a new diagnosis of epithelial ovarian cancer (any stage)?
- Are you about to start or currently receiving platinum-based chemotherapy?
- Are you able to provide written consent to take part?
- Você não está grávida ou amamentando?
- Do you not have recurrent ovarian cancer?
O que envolve a participação?
If you decide to take part in this study, you won't receive new or experimental treatments. Instead, you'll receive your standard platinum-based chemotherapy as recommended by your doctors. The main thing that changes for you is that some extra information will be collected during your regular hospital visits and treatments over a period of five years.
This means that during your routine appointments, doctors will record details about your health, your treatment journey, and your progress. They will also collect biological samples, such as blood, pieces of your tumour, and possibly fluid from your tummy if you have it. It's important to know that these samples will be taken at the same time as any samples you'd need for your standard care, so you won't need any additional procedures or extra biopsies just because you're in the study. Your total involvement in the study will last for five years.
Riscos e benefícios potenciais
Localizações (1)
- Institut Universitaire du Cancer de Toulouse - OncopoleCódigo postal verificadoToulouse, France· Recrutamento
Perguntas frequentes
What kind of ovarian cancer is this study for?
This study is for women with a newly diagnosed type of ovarian cancer called 'epithelial ovarian cancer'.
Will I get a new medicine or treatment in this study?
No, you will receive the standard chemotherapy treatment your doctor recommends for your cancer. This study is about understanding existing treatments.
Will I need extra tests or biopsies for the study?
No, any samples (like blood or tumour tissue) will be taken at the same time as your routine medical tests, so you won't have any extra procedures.
Por quanto tempo estarei envolvido no estudo?
If you join, you will be part of the study for five years.
Posso sair do estudo se mudar de ideia?
Yes, you can choose to leave the study at any time without it affecting your medical care.
Como saber mais
Gwenaël FERRON
Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.
Interessado em participar?
Discussão
Discussão da comunidade
Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.